skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Products

Show More

Resources

Show More

Information Types

Show More

Roles

Show More

Show More

Product Listing

3 product(s) and free and sample content

From: Biomedtracker

Biomedtracker: follow the drug development process

Track and assess key events that will impact a drug’s probability of technical success and approval.

  • Stay up to date
  • Get ahead of the competition
  • Conference coverage

Biomedtracker

BMT Q4 Outlook Report

27 Oct 2017

In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Topic Alzheimers Cancer Drug approval

Biomedtracker

Report Extract: Q3 2017 Outlook Report

17 Jul 2017

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Topic Alzheimers Cancer Drug approval

From: Trialtrove

Trialtrove: gold standard clinical trials intelligence

Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.

  • Curated by experts
  • Clinical trial landscape view
  • Standard of care insights

Trialtrove

Breast cancer PGX biomarker trials leading the way

By Doro Shin 09 Aug 2017

Breast cancer trials are making the most use of personalized medicine developments in trials, according to data gathered by Trialtrove.

Topic Clinical trials blog Clinical trials

Trialtrove, Medtrack

What is there to GAIN?

By Jonathan Slater 12 Jul 2017

The Generating Antibiotics Incentives Now (GAIN) Act passed into law on July 9, 2012. 

Topic Drug development landscape

From: Datamonitor Healthcare

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

  • Prioritize market opportunities
  • Identify unmet needs
  • Make informed decisions

Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 19 Sep 2017

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Topic Deal trends

Datamonitor Healthcare

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 19 Sep 2017

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Topic immuno-oncology

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: